In conclusion, CB1 receptor participated in ECs and induced lipogenesis in hepatocytes through factors SREBP-1c, ChREBP and LXRs, and might be the target for the treatment of NAFLD [25]. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.